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This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based 
research. The summary is not intended to be a comprehensive summary of available evidence on 
COVID-19 but aims to make original documents easily accessible to decision makers which, if 
relevant to them, they should go to before making decisions. 
Clinical characteristics and management 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
04.12.2020 Untuned 
antiviral 
immunity in 
COVID-19 
revealed by 
temporal 
type I/III 
interferon 
patterns 
and flu 
comparison 
Nature 
Immunology | 
Letter 
• A central paradigm of 
immunity is that interferon-
mediated antiviral responses 
precede pro-inflammatory 
ones optimising host 
protection and minimising 
collateral damage – here 
authors report that interferon-
mediated antiviral responses 
are diminished and delayed 
and preceded by pro-
inflammatory cytokines 
• Higher IFN-λ concentrations 
in patients with COVID-19 
correlated with lower viral 
load in bronchial aspirates 
and faster viral clearance 
• Altered cytokine patterns in 
patients with COVID-19 
correlated with longer 
hospitalisation and higher 
incidence of critical disease 
and mortality compared to flu 
Cytokine 
response 
Epidemiology and modelling  
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
04.12.2020 Infection and 
mortality of 
healthcare 
workers 
worldwide from 
COVID-19: a 
systematic 
review 
BMJ Global 
Health | 
Article 
• A total of 152 888 
infections and 1413 
deaths were 
reported 
• Infections were 
mainly in women 
(71.6%) and nurses 
(38.6%) but deaths 
were mainly in men 
(70.8%) and doctors 
(51.4%) 
• Limited data 
suggested that 
general practitioners 
and mental health 
nurses were the 
highest risk 
specialities for death 
• Most cases and 
deaths were 
reported in the 50-59 
age range, whilst the 
highest case fatality 
rate was reported in 
the group aged over 
70 years 
• Europe had the 
highest number of 
infections and 
deaths 
• Eastern 
Mediterranean 
region had the 
highest number of 
reported deaths per 
100 infections 
• Indian subcontinent 
and Africa reported 
a relatively low 
number of infections 
and deaths 
• Authors suggest that 
risks to healthcare 
workers, other than 
those with frequent 
exposure to 
oronasal secretions, 
should not be 
underestimated; 
Infection, 
mortality, 
healthcare 
workers 
elderly healthcare 
workers may require 
reassignment to less 
risky settings; and 
disparities between 
regions of the world 
may be a true 
differences or may 
reflect reporting and 
testing bias 
01.12.2020 Characterising 
COVID-19 
epidemic 
dynamics and 
mortality under-
ascertainment 
in Khartoum, 
Sudan 
ICL | Report 
39 
• Authors estimate 
that 2% (sensitivity 
range 2% to 5%) of 
deaths due to 
COVID-19 were 
officially reported, 
estimating 16,090 
(95% CI 14,300-
17,990) undetected 
COVID-19 deaths up 
to 20 November 
• Reductions in 
COVID-19 incidence 
during the first wave 
were due to both the 
implemented 
interventions and 
increasing immunity 
• The ending of 
stringent 
suppression 
measures in July 
resulted in 
transmission 
increasing 
• In the absence of 
implementing new 
suppressive 
measures, continued 
shielding of high risk 
individuals is 
important to help 
reduce mortality 
during the second 
wave 
• The second wave is 
predicted to peak 
before the beginning 
of 2021 and to be 
similar in size to the 
first wave sustained 
in the summer if 
transmission is 
maintained at 
current levels, 
Transmission, 
mortality 
under 
ascertainment, 
Khartoum, 
Sudan 
unless mortality 
under-ascertainment 
is at the upper end 
of the range (5%) in 
which case the 
authors estimate a 
smaller first wave 
24.11.2020 Transmission 
heterogeneities, 
kinetics, and 
controllability of 
SARS-CoV-2  
Science | 
Article 
• Based on detailed 
patient and contact 
tracing data in 
Hunan, China (1,178 
SARS-CoV-2 
infected individuals 
along with their 
15,648 contacts), 
authors find 80% of 
secondary infections 
traced back to 15% 
of SARS-CoV-2 
primary infections – 
this indicates 
substantial 
transmission 
heterogeneities 
• Transmission risk 
scales positively with 
the duration of 
exposure and the 
closeness of social 
interactions and is 
modulated by 
demographic and 
clinical factors 
• Lockdown increases 
transmission risk 
within the household 
while isolation and 
quarantine reduces 
risks across all types 
of contacts 
• Infectiousness in a 
SARS-CoV-2 
infected person 
peaks just before 
symptom 
presentation 
challenging 
epidemic control 
• Modelling indicates 
SARS-CoV-2 control 
requires the 
synergistic efforts of 
case isolation, 
contact quarantine, 
and population-level 
Transmission, 
infectiousness 
interventions to 
respond to the 
specific transmission 
kinetics of SARS-
CoV-2 
Therapeutics 
Publication 
date 
Title/URL Journal/Article 
type 
Summary             Keywords 
03.12.2020 Metformin 
and risk of 
mortality in 
patients 
hospitalised 
with COVID-
19: a 
retrospective 
cohort 
analysis 
The Lancet 
Health 
Longevity | 
Article 
• Retrospective cohort 
analysis of adult 
patients with type 2 
diabetes or obesity, 
both risk factors for 
severe COVID-19, 
admitted to hospital 
with PCR-confirmed 
COVID-19 
• Study showed 
metformin was 
significantly 
associated with 
reduced mortality in 
women with obesity 
or type 2 diabetes 
hospitalised with 
COVID-19 with use 
of metformin before 
diagnosis with 
SARS-CoV-2 
• Prospective studies 
are needed to 
understand 
mechanism and 
causality but given 
previously 
demonstrated 
effects of metformin 
on inflammation in 
women more than 
men, the main 
mechanism of 
benefit could be 
from reduced 
inflammation. Also 
this study of home 
metformin use 
highlights the effect 
that medications can 
have early on in the 
disease course 
Metformin, 
mortality, 
prevention, 
diabetes, obesity 
• If results are 
reproducible, 
metformin could be 
widely used before 
infection with SARS-
CoV-2 to prevent 
severe COVID-19 in 
patients with 
diabetes or obesity 
as it is safe and 
inexpensive 
02.12.2020 Repurposed 
antiviral 
drugs for 
Covid-19 – 
Interim 
WHO 
Solidarity 
Trial Results 
NEJM | Article 
• Results of 
SOLIDARITY trial 
now published 
• WHO expert groups 
recommended 
mortality trials of 4 
repurposed antiviral 
drugs – remdesivir, 
hydroxychloroquine, 
lopinavir and 
interferon beta-1a in 
patients hospitalised 
with COVID-19 
• At 405 hospitals in 
30 countries, 11,330 
adults underwent 
randomisation to 
one of five options 
(four drugs listed 
and the local 
standard of care) 
• None of the 
antivirals reduced 
overall mortality, 
initiation of 
ventilation and 
duration of hospital 
stay in patients 
hospitalised with 
Covid-19 
Solidarity trial, 
remdesivir, 
hydroxychloroquine, 
lopinavir, interferon 
beta-1a 
  
Vaccines 
Publication 
date 
Title/URL Journal/Article 
type 
Summary Keywords 
04.12.2020 Correlates 
of 
protection 
against 
SARS-
CoV-2 in 
rhesus 
macaques 
Nature | 
Article 
• Recent studies have 
reported protective efficacy 
of both natural immunity and 
vaccine-induced immunity 
against severe SARS-CoV-
2 challenge in rhesus 
macaques but protection 
against infection is yet to be 
determined 
• Here data show relatively 
low antibody titres are 
sufficient for protection 
against SARS-CoV-2 in 
rhesus macaques and that 
cellular immune responses 
may also contribute to 
protection if antibody 
responses are suboptimal 
Correlates 
of 
protection, 
SARS-
CoV-2 
infection 
Comments, Editorials, Opinions, Blogs, News 
 Publication 
date 
Title/URL Journal | Article type 
07.12.2020 COVID-19: what health experts could and could 
not predict 
Nature Medicine | World view 
05.12.2020 An African plan to control COVID-19 is urgently 
needed 
The Lancet Editorial 
05.12.2020 South Africa and India push for COVID-19 
patents ban 
The Lancet | World Report 
03.12.2020 WHO at the Special Session of the United 
Nations General Assembly in Response to the 
Coronavirus Disease (COVID-19) Pandemic 
WHO | News 
03.12.2020 Antibody testing could lend a hand to global 
vaccine programs crippled by COVID-19 
PLOS | Blog 
03.12.2020 COVID-19 vaccine trial ethics once we have 
efficacious vaccines 
Science | Policy forum 
02.12.2020 Could COVID delirium bring on dementia?  Nature | News 
30.11.2020 Incentivising wealthy nations to participate in 
the COVID-19 Vaccine Global Access Facility 
(COVAX): a game theory perspective 
BMJ Global Health | 
Commentary 
30.11.2020 Accelerating progress of low-income countries 
towards the SDGs: balancing realism and 
ambition in a post-COVID-19 world 
CGD | Policy Paper 
30.11.2020 Sustaining low-income countries’ progress 
towards the SDGs in a post-CoVID-19 world: 
what is achievable? 
CGD | Blog 
30.11.2020 Afro-European Partnerships in Health: 
Accelerating better efficiency of health spending 
CGD | Blog 
30.11.2020 Where are women and girls especially 
vulnerable to the COVID-19 pandemic? 
CGD | Blog 
30.11.2020 We are facing an unprecedented global 
challenge to protect every country from COVID-
19 
World Bank | Blog 
Guidelines, Statements & Tools 
 Publication 
Date 
Title/URL Source   Summary 
07.12.2020 Antigen rapid tests: 
training package 
FIND | 
Training 
materials 
• Training package for COVID-19 
antigen rapid diagnostic tests 
developed by FIND with WHO 
• Materials are free to download 
and can be adapted based on 
national guidelines 
15.10.2020 Behavioural 
considerations for 
acceptance and 
WHO 
Technical 
Advisory 
Group on 
• The report follows a meeting and 
subsequent iterative process 
between the WHO TAG on 
Behavioural Insights and 
Sciences for Health with the 
uptake of COVID-
19 vaccines 
Behavioural 
Insights and 
Science for 
Health | 
Meeting 
Report 
WHO Department of 
Immunization, Vaccines and 
Biologicals to discuss 
behavioural considerations in 
relation to COVID-19 vaccine 
acceptance and uptake 
• Behavioural research has shown 
that vaccine acceptance and 
uptake can be increased by 
adopting three strategies (1) 
creating an enabling 
environment; (2) harnessing 
social influences; and (3) 
increasing motivation 
• A common theme is engagement 
with local community 
   
 
Dashboards & Trackers 
Cases & deaths: 
Global 
Cases & 
deaths: 
Regional 
Cases & 
deaths: 
Country 
Living evidence & 
policy maps 
Current research 
including trials 
  Diagnostics   Treatments   Vaccines 
WHO sitreps  WHO Africa  Ghana  COVID-NMA  WHO    FIND SARS-
CoV-2 Test 
Tracker 
  Global COVID-
19 Clinical Trial 
Tracker 
  CEPI 
WHO dashboard  African 
Arguments  
Indonesia  EPPI Centre  WHO International 
Clinical Trials 
Registry Platform 
(ICTRP)  
 FIND SARS-
CoV-2 
Diagnostics: 
performance 
data 
  US NIH 
registered 
clinical trials 
Vaccine 
Centre 
LSHTM  
Johns Hopkins 
University  
European 
CDC  
Nigeria CDC  Norwegian 
Institute of Public 
Health  
Cytel   Serology-based 
tests for COVID-
19 
  Solidarity trial  COVID-19 
Oxford 
Vaccine Trial 
WEF    Sierra Leone   Oxford C19 
Government 
Response 
Tracker 
(OxCGRT) 
US NIH   Our World in 
Data: C19 
Testing 
  COVID-19 
Therapeutics 
Accelerator 
 COVID-19 
Vaccine 
Tracker 
Our World in 
Data  
  Singapore   Our World in 
Data: C19 Policy 
responses 
COVID-evidence        
Global 5050    UK   IFPRI COVID-19 
Policy Response 
Portal 
Cochrane        
CEBM, University 
of Oxford  
  US   COVID-19 
Primer 
Clinicaltrials.gov        
Humanitarian 
Data Exchange  
     NIH LitCovid  UKCDR       
Information is 
Beautiful  
     WHO COVID-19 
Database 
        
LSHTM                
HealthMap 
(cases) 
              
The Commons 
Project 
              
SeroTracker                
   
 
C19 Resource Hubs 
Global  Regional & 
Country 
Academic 
journals & 
Publishers 
Institutes/Centres
/Funders/Other 
Health Topics   Social 
Sciences 
WHO COVID-
19 pandemic  
Africa CDC Annals of 
Internal 
Medicine 
LSTM Stop TB 
Partnership 
  SSHAP 
WHO risk 
communication 
African 
Union 
BMJ LSHTM 
 
  IDA 
WHO Q&A Nigeria 
CDC 
Bulletin of 
the WHO 
ICL MRC Centre 
for Global 
Infectious 
Disease Analysis 
Global 
Menstrual 
Collective  
  Disability 
and inclusion 
WHO Global 
research 
GeoPoll: 
SSA 
Cambridge 
University 
Press 
ODI SLH: 
Handwashing 
in low 
resource 
settings 
  Coregroup 
IDDC 
COVID-19 
Solidarity 
Response Fund 
Global 
Health 
Network 
Africa 
Cell Press Johns Hopkins 
University 
RBM 
Partnership 
  Ethics, 
health 
systems & 
COVID-19 
UN African 
Academy of 
Sciences 
Cochrane  Center for Global 
Development 
 Epidemic 
Preparedness 
Innovations 
  Social 
Development 
Direct C19 
blog series 
UN Women Africa 
Evidence 
Network 
Elsevier CMMID 
Repository 
    
UNOCHA OCHA 
Southern 
and Eastern 
Africa 
Health 
Policy and 
Planning  
Norwegian 
Institute of Public 
Health 
    
COVID-19 
Digest 
UNHCR  South 
African 
Government 
JAMA 
Network 
Oxford Centre for 
Evidence-based 
Medicine 
    
UNICEF   The 
Lancet 
 HEART     
UNESCO   medRxiv 
and 
bioRxiv 
(Preprints) 
 UKRI     
UN WFP   NEJM  Evidence Aid     
GOARN   Oxford 
University 
Press 
 NIH     
EPI-WIN   PLoS IFPRI Resources 
and Analyses of 
C19 Impact 
    
World Bank   SAGE 
journals 
 Prevent 
Epidemics  
    
Our World in 
Data 
  Science       
COVID-19 
Narratives by 
David Nabarro 
  Springer 
Nature 
      
Reliefweb   SSRN 
(Preprints)  
      
Humanitarian 
OpenStreetMap 
Team 
  Wiley       
Global 
Partnership for 
Sustainable 
Development 
Data 
  
 
      
WorldPop           
Flowminder           
COVID-END           
Premise 
COVID-19 
Global Impact 
Study 
    
  
GISAID           
Online learning & events 
 Date Title/URL Online 
learning/event 
Duration Lead 
04.12.2020 COVID-19, supply 
chain resilience and 
global trade 
Webinar 1h CGD 
03.12.2020 More money for 
health services: What 
is the tole of PFM in 
the “new normal”? 
WHO & CGD 
Health systems 
Governance & 
Financing 
1h 30 Joe Kutzin 
01.12.2020 Solutions and support 
for the mental 
wellbeing of 
community health 
workers on the 
COVID-19 frontline 
Webinar   HSG TWG on CHWs 
with The George 
Institute for Global 
Health 
19.11.2020 Looking at the 
pandemic with a 
gender lens 
Live Twitter 
conversation 
  SSHAP 
16.11.2020 HIFA and WHO 
collaborate to 
promote sharing of 
experience and 
expertise around the 
maintenance of 
essential health 
services during (and 
after) the pandemic 
4-week 
discussion 
starting 16 Nov 
  HIFA 
10.11.2020 COVID-19 vaccine 
predictions part 2: 
estimating the time 
before we approve 
efficacious COVID-19 
vaccines 
Online event 1h30 CGD 
16.10.2020 Financing a Global 
Public Health 
Response 
Online event 1h30 CGD 
02.10.2020 Understanding and 
Improving COVID-19 
Vaccine Portfolio 
Online event 1h30 CGD 
21.09.2020 Mitigating the 
Economic and Health 
Impact of COVID-19 
across Africa 
Online event 1h30 CGD, GF, AU 
June 2020 OpenWHO, the free, 
open-access learning 
platform for health 
emergencies, now 
offers 10 online 
courses related to 
COVID19. 
Online courses Varies WHO 
Available 
now 
Standard 
precautions: 
Environmental 
cleaning and 
disinfection 
Online course 1 hour WHO 
Available 
now 
COVID-19: Effective 
Nursing in Times of 
Crisis 
Online course 2 weeks – 
2 hours 
per week 
Johns Hopkins School 
of Nursing 
Available 
now 
WHO Academy and 
WHO Info mobile 
applications 
Mobile app   WHO 
Available 
now 
COVID-19: 
Pandemics, 
Modelling and Policy 
Online learning 2 weeks | 
2 hours 
weekly 
study 
FutureLearn UNESCO 
UNITWIN Complex 
Systems Digital 
Campus/Open 
University 
11.5.2020 COVID-19 Contact 
Tracing course 
Online learning 5 hours Johns Hopkins 
Bloomberg School of 
Health 
7-28 May 
2020 
Virtual Evidence 
Weeks 
5 sessions 1h 30 International Initiative 
for Impact Evaluation 
(3ie) 
Tuesdays 
at 1700 
CEST 
(Geneva 
time) & 
Thursdays 
0830 CEST 
(Geneva 
time) 
COVID-19 Open 
online brief with Dr 
David Nabarro 
Event 1h 4SD 
Available 
now 
Emerging respiratory 
viruses, including 
COVID-19: methods 
for detection, 
Online learning 3 hours WHO 
prevention, response 
and control 
Available 
now 
Responding to 
COVID-19: Real-time 
training for the 
coronavirus disease 
outbreak 
Online learning Multiple 
self-paced 
course 
WHO 
25 May 
2020 
COVID-19: Tackling 
the Novel 
Coronavirus 
Online learning 3 weeks | 
4 hours 
weekly 
study 
FutureLearn 
LSHTM/UK PHRST 
Available 
online now 
without 
mentors. 
Updated 
version will 
commence 
early June 
2020 
COVID-19 
Diagnostics and 
Testing 
Online learning 3 weeks | 
3 hours 
weekly 
study 
FutureLearn 
FIND/LSHTM/ASLM 
6 April 2020 COVID-19 Critical 
Care: Understanding 
and Application 
Online learning 5 weeks | 
1 hour 
weekly 
study 
FutureLearn University 
of Edinburgh & Royal 
College of Physicians 
of Edinburgh  
Available 
now 
COVID-19 supporting 
online courses 
Online learning Multiple 
self-paced 
course 
BMJ Learning 
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Rapid review methodology 
The rapid weekly search for peer-reviewed literature is carried out through a PubMed search with the following 
keywords (“COVID-19” OR “severe acute respiratory syndrome coronavirus 2” OR “2019-nCoV” OR “SARS-CoV-
2” OR “2019nCoV” OR “coronavirus” ) AND (“Africa” OR “South Asia” OR “Developing” OR “low-income” OR “low 
income” OR “lower-middle income” OR “low and middle income” OR “LMIC” OR “LIC” OR “global south”) OR 
(“poverty”) OR (“equity” OR “equities”), restricted to articles published in the previous 2 to 3 days, in English. This 
is complemented by a search of the homepage of the following high-impact global health journals: The Lancet 
journals, New England Journal of Medicine, Nature, JAMA, Annals of Internal Medicine, Cochrane Reviews, BMJ 
Global Health, the PLoS journals and a Twitter search of their Twitter pages. A search also of preprints from bioRxiv 
and medRxiv. Please note that papers that have not been peer-reviewed are highlighted in red. All primary research 
papers that relate to the primary and secondary impacts of the COVID-19 response in LMICs, and disease control 
and health system responses are included. Articles related to tackling the secondary impacts on other sectors are 
not included. Additional commentaries, opinions, and commissioned pieces are selected based on relevance. 
 The search for dashboards, guidelines, tools, editorials, comments, blogs, opinions and news is through the 
academic journals listed above, C19 resource hubs and following lead academics and professionals on Twitter. 
 
About this report  
This weekly COVID-19 health evidence summary (HES) is based on 3.5 hours of desk-based research. The 
summary is not intended to be a comprehensive summary of available evidence on COVID-19 but aims to make 
original documents easily accessible to decision makers which, if relevant to them, they should go to before making 
decisions. The HES are not intended to replace medical or professional advice and the researcher or the K4D 
consortium cannot be held responsible for any decisions made about COVID-19 on the basis of the HES alone. 
K4D services are provided by a consortium of leading organisations working in international development, led by 
the Institute of Development Studies (IDS), with Education Development Trust, Itad, University of Leeds Nuffield 
Centre for International Health and Development, Liverpool School of Tropical Medicine (LSTM), University of 
Birmingham International Development Department (IDD) and the University of Manchester Humanitarian and 
Conflict Response Institute (HCRI). 
This evidence summary was prepared for the UK Government’s Foreign, Commonwealth 
and Development Office (FCDO) and its partners in support of pro-poor programmes. Except 
where otherwise stated, it is licensed for non-commercial purposes under the terms of the 
Open Government Licence v3.0. K4D cannot be held responsible for errors, omissions or 
any consequences arising from the use of information contained in this health evidence 
summary. Any views and opinions expressed do not necessarily reflect those of FCDO, K4D 
or any other contributing organisation.  
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